Continuous studies have been made on the pathophysiology of hyperphosphatemia, evaluation of therapies on the clinical outcomes, and guidelines have shaped the evidence underlying current and emerging treatment options. Concurrently, the body of clinical evidence supporting common medications in various patient populations has also evolved, paving way to state-of-art management strategies. A number of clinical development programs led by pharmaceutical companies have further shaped the evolution of the hyperphosphatemia treatment market.
Various causes have been identified for hyperphosphatemia and the mechanisms by which phosphates are implicated in the outcomes guide the optimal interventions, thus influencing the dynamics of the hyperphosphatemia market. One of the most causes is renal failure; less- known causes are high intake of phosphorus and increased renal reabsorption. Genetic factors notably hyperparathyroidism and pseudohypoparathyroidism lead to hyperphosphatemia. Cardiovascular risks mandate early intervention in order to reduce the morbidity associated with hyperphosphatemia.
Over the past few years, the need for treatment of hyperphosphatemia in patients with kidney disease has propelled several basic and animal-based clinical studies. These have enriched the landscape of the hyperphosphatemia treatment market. There is an unmet need for robust strategies pertaining to the prevention and the treatment of hyperphosphatemia. This has broadened the range of phosphate binders along with dietary modifications.
The rise in incidence of end-stage renal disease incidence is a key trend bolstering the prospects for new pharmacological interventions in the hyperphosphatemia treatment market. The current management options point toward adopting integrated approach to reduce elevated phosphorus and calcium levels. High risk of cardiovascular events in the patient population has intensified the need for an multidisciplinary approach to its management, including the treatment. There seems to be an unmet need for developing calcium acetate/magnesium combination products in the hyperphosphatemia treatment market. Of particular interest is the new class of phosphate binders. Consequently, there is intense need for clinical trials that squarely look at testing them for their efficacy, tolerability, and safety in advanced chronic kidney disease (CKD).
The focus of players in the healthcare industry to promote patients’ pill burden and out-of-pocket costs is a key factor that has been shaping the growth trajectories of the hyperphosphatemia treatment market. The growing popularity of gastrointestinal phosphate binders as one of the most widely prescribed medications for patients with CKD is a key trend that has influenced the trajectories.
Extensive studies have been conducted the patients with CKD glomerular filtration rate category 3a (G3a) and glomerular filtration rate categories 3-5 (G3-G5) that offer well-rounded evidence against clinical practice guidelines. Interestingly, this has also guided biotech and pharmaceutical companies conducting clinical studies on oncology for taking into consideration the adverse impacts of hyperphosphatemia. This has positively impacted the hyperphosphatemia market. A recent study by Janssen has lookws into detail of the adverse investigational treatments for solid tumors and hematologic malignancies.
In another study of a different kind, National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) has conducted a poll on evaluating whether calcium-based phosphate binders are an optimal choice in patients with CKD, in the backdrop of the fact that there is a predominant use of phosphate binders in CKD G5D. Such studies help in lowering the pill burden in chronic kidney disease patients and will pave way to better therapies in the global hyperphosphatemia market.
Growing body of studies in the U.S. and the U.K. have enriched the evidence for phosphate-binding therapy. North America has been a potentially lucrative region in the global hyperphosphatemia treatment market, with growing focus of healthcare providers in implementing The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. The prevalence of use of different phosphate-binders in dialysis patients has spurred several studies in the U.S., thereby bolstering the revenue prospect of the North America hyperphosphatemia treatment market.
Interested in this report?
Get a FREE Brochure now!
*Get Brochure (PDF) sent to your email within minutes
Complete the form below and we'll get back to you shortly.